These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 25129081)

  • 1. [Primary and secondary prophylactic administration of granulocyte-colony stimulating factor(G-CSF)for febrile neutropenia].
    Uchino K; Baba E
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):691-3. PubMed ID: 25129081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Use of granulocyte-colony stimulating factor(G-CSF)in patients with cancer at high risk of febrile neutropenia on the basis of high age and complications, recommendations for patients receiving radiotherapy, and adverse events because of G-CSF].
    Hanada N; Tanaka S; Takahata T; Sato A
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):702-6. PubMed ID: 25129083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Overview of guidelines for proper use of the G-CSF(2013 edition)].
    Kiura K
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):687-90. PubMed ID: 25129080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary granulocyte colony-stimulating factor prophylaxis during the first two cycles only or throughout all chemotherapy cycles in patients with breast cancer at risk for febrile neutropenia.
    Aarts MJ; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4290-6. PubMed ID: 23630211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Appropriate use of granulocyte-colony stimulating factor in treating hematologic malignancies].
    Usui N
    Rinsho Ketsueki; 2015 Oct; 56(10):2267-76. PubMed ID: 26458468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary prophylactic granulocyte colony-stimulating factor according to ASCO guidelines has no preventive effect on febrile neutropenia in patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
    Kawahira M; Yokota T; Hamauchi S; Kawai S; Yoshida Y; Onozawa Y; Tsushima T; Todaka A; Machida N; Yamazaki K; Fukutomi A; Yasui H
    Int J Clin Oncol; 2018 Dec; 23(6):1189-1195. PubMed ID: 29948238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antineoplastic drug-induced neutropenia: use of granulocyte colony stimulating factors].
    Carrato A; Guillén-Ponce C; Grande-Pulido E
    Farm Hosp; 2010 Mar; 34 Suppl 1():8-11. PubMed ID: 20920851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
    Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
    Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
    Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
    J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J; Bramwell V; Stephenson B
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
    Krzemieniecki K; Sevelda P; Erdkamp F; Smakal M; Schwenkglenks M; Puertas J; Trojan A; Szabo Z; Bendall K; Maenpaa J
    Support Care Cancer; 2014 Mar; 22(3):667-77. PubMed ID: 24154740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
    Freyer G; Kalinka-Warzocha E; Syrigos K; Marinca M; Tonini G; Ng SL; Wong ZW; Salar A; Steger G; Abdelsalam M; DeCosta L; Szabo Z
    Med Oncol; 2015 Oct; 32(10):236. PubMed ID: 26315712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Tips on the use of granulocyte colony-stimulating factors in cancer patients predisposed to chemotherapy - induced febrile neutropenia].
    Murakawa Y
    Gan To Kagaku Ryoho; 2013 Jun; 40(6):693-6. PubMed ID: 23863645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.
    Fust K; Parthan A; Maschio M; Gu Q; Li X; Lyman GH; Tzivelekis S; Villa G; Weinstein MC
    Expert Rev Pharmacoecon Outcomes Res; 2017 Feb; 17(1):39-52. PubMed ID: 28064553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
    Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
    Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical use of granulocyte-colony stimulating factor.
    Shah J; Welsh SJ
    Br J Hosp Med (Lond); 2014 Feb; 75(2):C29-32. PubMed ID: 24521833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.